232 related articles for article (PubMed ID: 35550553)
1. Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome.
Gorris MAJ; van der Woude LL; Kroeze LI; Bol K; Verrijp K; Amir AL; Meek J; Textor J; Figdor CG; de Vries IJM
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550553
[TBL] [Abstract][Full Text] [Related]
2. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
3. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L
Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934
[TBL] [Abstract][Full Text] [Related]
4. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Rohaan MW; Borch TH; van den Berg JH; Met Ö; Kessels R; Geukes Foppen MH; Stoltenborg Granhøj J; Nuijen B; Nijenhuis C; Jedema I; van Zon M; Scheij S; Beijnen JH; Hansen M; Voermans C; Noringriis IM; Monberg TJ; Holmstroem RB; Wever LDV; van Dijk M; Grijpink-Ongering LG; Valkenet LHM; Torres Acosta A; Karger M; Borgers JSW; Ten Ham RMT; Retèl VP; van Harten WH; Lalezari F; van Tinteren H; van der Veldt AAM; Hospers GAP; Stevense-den Boer MAM; Suijkerbuijk KPM; Aarts MJB; Piersma D; van den Eertwegh AJM; de Groot JB; Vreugdenhil G; Kapiteijn E; Boers-Sonderen MJ; Fiets WE; van den Berkmortel FWPJ; Ellebaek E; Hölmich LR; van Akkooi ACJ; van Houdt WJ; Wouters MWJM; van Thienen JV; Blank CU; Meerveld-Eggink A; Klobuch S; Wilgenhof S; Schumacher TN; Donia M; Svane IM; Haanen JBAG
N Engl J Med; 2022 Dec; 387(23):2113-2125. PubMed ID: 36477031
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases.
Steindl A; Alpar D; Heller G; Mair MJ; Gatterbauer B; Dieckmann K; Widhalm G; Hainfellner JA; Schmidinger M; Bock C; Müllauer L; Preusser M; Berghoff AS
ESMO Open; 2021 Apr; 6(2):100057. PubMed ID: 33588158
[TBL] [Abstract][Full Text] [Related]
7. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma.
Wong PF; Wei W; Smithy JW; Acs B; Toki MI; Blenman KRM; Zelterman D; Kluger HM; Rimm DL
Clin Cancer Res; 2019 Apr; 25(8):2442-2449. PubMed ID: 30617133
[TBL] [Abstract][Full Text] [Related]
8. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
9. Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.
Georgoulias G; Zaravinos A
Front Immunol; 2022; 13():1006665. PubMed ID: 36389735
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
BMC Cancer; 2018 Apr; 18(1):371. PubMed ID: 29614981
[TBL] [Abstract][Full Text] [Related]
11. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy.
Balatoni T; Mohos A; Papp E; Sebestyén T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Gaudi I; Ladányi A
Cancer Immunol Immunother; 2018 Jan; 67(1):141-151. PubMed ID: 28988380
[TBL] [Abstract][Full Text] [Related]
13. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.
Maibach F; Sadozai H; Seyed Jafari SM; Hunger RE; Schenk M
Front Immunol; 2020; 11():2105. PubMed ID: 33013886
[TBL] [Abstract][Full Text] [Related]
14. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
15. Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma.
Ladányi A; Papp E; Mohos A; Balatoni T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Ferrone S
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554608
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
18. Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial).
Googe PB; Theocharis S; Pergaris A; Li H; Yan Y; McKenna EF; Moschos SJ
Curr Probl Cancer; 2022 Jun; 46(3):100862. PubMed ID: 35398635
[TBL] [Abstract][Full Text] [Related]
19. Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients.
Freiberger SN; Holzmann D; Morand GB; Hüllner M; Levesque MP; Dummer R; Koelzer VH; Rupp NJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5645-5653. PubMed ID: 36527482
[TBL] [Abstract][Full Text] [Related]
20. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.
Retèl VP; Steuten LMG; Geukes Foppen MH; Mewes JC; Lindenberg MA; Haanen JBAG; van Harten WH
BMC Cancer; 2018 Sep; 18(1):895. PubMed ID: 30219040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
